Cellular Health Screening Market Size, Share | Report 2022-2030
The global cellular health screening market was surpassed at USD 2.6 billion in 2021 and is expected to hit around USD 5.8 billion by 2030, growing at a CAGR of 9.32% from 2022 to 2030.
Report Highlights
The growing geriatric population and consequent growth in the requirement for cellular health screening are majorly driving the market. In addition, the rising adoption of the direct-to-consumer approach, the growing importance of healthy life expectancy (HALE), increasing telomere performance programs for leading a healthy life, and rising government focus on preventive healthcare are expected to drive the market.
An increasing number of individuals undergoing cellular health screening testing, such as telomere tests, to learn about the biomarkers of cell aging is also anticipated to supplement the market growth. It has been demonstrated that tests that provide information on telomere length and activity can also provide information on lifestyle and stress factors. Numerous studies have demonstrated that both acute stress and chronic stress accelerate cell aging. Thus, these tests play an important role in understanding one’s health.
Additionally, researchers can gain insights into cellular qualities by studying how physical exercise, sleep, mental health issues, alcohol use, and smoking habits alter cellular aging in various ways. The utilization of telomere tests offers insights into metabolic and genetic illnesses, enabling clinicians to make an early diagnosis and quickly and individually tailor a patient's treatment regimen. Consequently, growing interest in cellular screening and expanding research have increased kit and test demand, facilitating market growth in recent years.
The necessity for cellular screening research has grown as a result of its many applications in preventive medicine and the capacity to comprehend relationships between telomere length and aging. Bio-cell-based screenings are frequently advised throughout time, allowing patients to compare results and comprehend what modifications need to be made. Monitoring these alterations in cellular health between screenings enables quick adjustments to be made in terms of health protocols and a general improvement in illness management.
Furthermore, disorders related to aging are linked to the buildup of old, dysfunctional cells. As shown in several animal trials, research has recently established that these can be reversed by employing a variety of cellular health procedures. Consequently, it is anticipated that ongoing research and development activities in the disciplines of protein expression, proteomics, and genomics are anticipated to further boost the demand for cellular health screening products in the near future.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 2.6 billion |
| Revenue Forecast by 2030 | USD 5.8 billion |
| Growth rate from 2022 to 2030 | CAGR of 9.32% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Test type, sample type, collection site, region |
| Companies Covered |
Telomere Diagnostics; SpectraCell Laboratories; Life Length; Repeat Diagnostics, Inc.; Cell Science Systems Corp.; Quest Diagnostics; LabCorp Holdings; OPKO; Genova Diagnostics; Immundiagnostik AG; DNA Labs |
Test Type Insights
The single test panels segment held the largest share of over 75.05% in 2021. Among the cellular health screening tests for telomere, inflammation, oxidative stress, and heavy metals, the telomere single test panel is expected to grow at the fastest rate over the forecast period. This can be attributed to various research studies showing the correlation of telomere length on multiple molecular and cellular functions. Moreover, the launch of new testing devices for the detection of telomere length further contributes to the growth. For instance, in September 2021, Genomic Vision launched TeloSizer to boost the use of telomere for biomarker discovery via its precise and quantitative detection.
The multi-test panels segment is estimated to witness the fastest growth during the forecast period. The utilization of these panels for screening multiple biomarkers during a single run has resulted in many advantages such as diagnostic competence, precision, and reduced costs in health care settings. These reasons are anticipated to increase the inclination toward multi-test panels rather than single-use panels in the future.
Sample Type Insights
Blood sample dominated the market with a share of over 45.12% in 2021. The frequent use of blood samples by clinicians and the application of diagnostic kits for evaluating various disease conditions, organ functioning, and risk factor analysis are the factors supporting the growth of the segment. Additionally, the launch of new diagnostic devices that use blood for detection and screening is boosting market growth. For instance, a blood-testing startup, Osler is tapping investors for funds before the big launch of its diagnostic device. The new technology will deliver results in 10 minutes and it aims at providing cheap blood tests.
Urine sample will observe significant growth in the forecast period. Urine collection is patient-friendly as it is non-invasive and much quicker because it doesn’t require technical personnel. Research has also demonstrated that oxidative stress can be successfully evaluated from urine screening. For instance, in a research article published in July 2020, researchers from Japan proved that the presence of pteridine derivatives in urine is associated with oxidative stress and smoking. Thus, the increased testing of oxidative stress in the human body is also expected to fuel the growth of urine sample type screening in the market.
Collection Site Insights
In 2021, the hospital segment accounted for the largest revenue share of over 35.06%. For the majority of the population, hospitals are the center for primary diagnosis and treatment. The use of diagnostic kits for both in-patients and out-bound patients for health screening is one of the major factors contributing to the growth. Moreover, the presence of medical professionals and the recommendation of diagnostic tests for disease identification are fueling the growth of the market. The presence of sample collection sites, skilled professionals, and advanced diagnostic techniques in one place is anticipated to further contribute to the growth.
The home segment is estimated to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing awareness regarding health and self-sampling adoption in major markets. The adoption of self-sampling is because it is user-friendly and doesn’t require specific infrastructure or trained professionals. Moreover, the COVID-19 pandemic led to the mass preference for home collections due to limited movements and this preference will continue even in the years to come. For example, Lab Corp announced in April 2022 that it has launched a home collection service for various diagnostic and screening test offerings of the company.
Regional Insights
North America accounted for a dominant share of over 45.15% in 2021. The rising awareness regarding health among individuals driving the Healthy Life Expectancy (HALE), growing healthcare expenditure, and government funding for preventative healthcare are some of the key contributing factors in this region. Furthermore, the presence of major key players, easy adoption of new technologies, and the burden of infectious and chronic diseases in the population are contributing to regional growth.
Asia Pacific is expected to emerge as the fastest-growing regional market over the forecast period. This is owing to the presence of a growing population that contributes to a larger patient pool and the developing healthcare infrastructure due to increasing economies. The improved adoption of tests and health consciousness among adult individuals are the key driving factors in the Asia Pacific. Moreover, the increased research on telomere for senescence and government initiatives for the prevention of diseases is supporting regional growth.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cellular Health Screening Market
5.1. COVID-19 Landscape: Cellular Health Screening Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cellular Health Screening Market, By Test Type
8.1. Cellular Health Screening Market, by Test Type, 2022-2030
8.1.1 Single Test Panels
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Multi-test Panels
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cellular Health Screening Market, By Sample Type
9.1. Cellular Health Screening Market, by Sample Type, 2022-2030
9.1.1. Blood
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Saliva
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Serum
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Urine
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cellular Health Screening Market, By Collection Site
10.1. Cellular Health Screening Market, by Collection Site, 2022-2030
10.1.1. Home
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Office
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Hospital
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Diagnostic Labs
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cellular Health Screening Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.1.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.5.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Collection Site (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Test Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Collection Site (2017-2030)
Chapter 12. Company Profiles
12.1. Telomere Diagnostics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. SpectraCell Laboratories
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Life Length
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Repeat Diagnostics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cell Science Systems Corp.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Quest Diagnostics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. LabCorp Holdings
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. OPKO
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Genova Diagnostics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Immundiagnostik AG
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers